JDI
23.8.2024 09:01:29 CEST | Business Wire | Press release
This press release is intended to redistribute the content that was already disclosed on August 2, 2024, for an international audience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240823676155/en/
2 Vision Display (Graphic: Business Wire)
JDI has developed the world's first 2 Vision Display (2VD) technology that meets automotive grade image quality requirements while simultaneously displaying different image content based on viewing direction. As another world's first, JDI has incorporated Dual Touch into its new 2VD technology that identifies discrete touch operations from different users. JDI Dual Touch 2VD thus enables a single display to function as two separate touch-enabled displays.
2VD has existed as a concept for many years. Unfortunately, it has historically been unable to overcome image quality issues to achieve commercialization and product use.
With its new Dual Touch 2VD technology, JDI has deployed its world-leading LTPS and optics capabilities to generate the necessary breakthrough in image quality to allow for widespread use. As an automotive use case, JDI Dual Touch 2VD simultaneously provides a large-screen, rich-content information display to the driver to support safe driving and a large-screen, high-quality passenger display on a single display. Dual Touch 2VD also resolves interior design constraints caused by the increase in displays, while allowing the reduction of in-car display usage to support streamlined and sophisticated interior designs.
2VD has also historically lacked touch functionality, an important capability for many use cases. JDI Dual Touch 2VD uses JDI-developed custom ICs to identify whether touch operations originate from the driver or passenger (again, using an automotive use case example), allowing a single display to function as two separate touch-enabled displays.
JDI is currently in discussions with multiple global automobile OEMs to incorporate JDI Dual Touch 2VD into their next-generation vehicle interiors, with first shipment possible as early as 2025. In collaboration with these OEMs, JDI is working to create unprecedented levels of automobile safety and comfort.
Existing 2VD vs. New JDI Dual Touch 2VD |
||
|
Existing 2VD |
New JDI Dual Touch 2VD |
Resolution |
88 ppi |
171 ppi |
Brightness |
350 nits |
700 nits |
Contrast |
350 : 1 |
1000 : 1 |
NTSC Ratio |
70% |
85% |
Touch Functionality |
None |
Dual Touch |
Furthermore, JDI Dual Touch 2VD’s rich functionality goes beyond the automotive industry. It has a broad set of use cases in an extraordinarily rich variety of contexts, locations, and industries and in both horizontal and vertical 2VD modes. As examples, JDI Dual Touch 2VD can be deployed in large signage applications or to create display security and privacy enhancements through viewing angle control, or to support innovative gaming applications.
A sample vertical use case of JDI Dual Touch 2VD would be a large display at a transportation hub such as an airport or train station, in which the changing user viewing angle, depending on the distance between the display and the user, allows for the simultaneous provision of rich visuals, art or other creative content, general information, or advertising (at a distance) and departure/arrival information (up close).
JDI Dual Touch 2VD is a breakthrough display technology that has the potential to change the way displays are used – and shared – all over the world in fundamentally new ways. JDI looks forward to open innovation and collaboration with individuals, organizations, and creative communities globally to explore new use cases for JDI Dual Touch 2VD that enrich people’s daily lives. Please feel free to contact us at:
https://www.webcoms.jp/jdi/eng/form.php?pid=524
2 Vision Display presentation video
https://youtu.be/zBnz1GirUYE
[Provisional Translation Only]
This translation is provided solely for information purposes.
Should there be any discrepancies between this translation and the Japanese original, the latter shall prevail.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240823676155/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
